The present invention relates to oral extended release composition, comprising memantine or its pharmaceutically acceptable salt as an active ingredient, resin complexation ingredient, release retardant, extended release coating system and the composition further comprising diluents, viscosity increasing agents, glidants, sweeteners, stabilizing agents, preservatives and other pharmaceutically acceptable excipients, wherein the drug-resin complex and drug-resin complex matrix particulates and coated drug-resin complex particulates have the specific particle size range. The present invention also relates to a process for the preparation of memantine or its salt oral extended release composition comprising the steps of drug-resin complexation, matrix resinate/particulates preparation process followed by extended release coating. The present invention also relates to oral extended release composition comprising memantine or its pharmaceutically acceptable salt as an active ingredient and pharmaceutically acceptable excipients using extended release resin-complexation technology, further comprising additional active ingredient is in its immediate release form.

Disclosed herein is a method for the preparation of an amorphous solid dispersion (ASD) comprising the steps of providing an aqueous suspension comprising nano-particles having a solubility in the aqueous suspension of less than 10 g/1, water and at least one polymer, nano-dry-melting of the aqueous suspension comprising nano-particles for a time span between 0.1 seconds and 300 seconds, at a temperature between a) 20 K below the glass transition temperature as determined with DSC according to DIN EN ISO 11357-2 at a heating rate of 10 K/min of the solid components of the aqueous suspension comprising nano-particles or 20 K below the glass transition temperature of the at least one polymer, depending on what is higher, b) the decomposition temperature of the at least one polymer or the decomposition temperature of the nano-particles, depending which is lowerto form the amorphous solid dispersion.

There is provided a method of preparing a hybrid capsule, the method comprising heterocoagulating organic polymer latex particles with a primary capsule to form an organic polymer coating layer over a shell of the primary capsule.

Systems and methods for localized drug delivery via undulating drug coated balloons (DCB), in particular using functionalized nanoparticles as a drug delivery medium in combination with an undulating balloon, are disclosed. In various disclosed embodiments, a nanoparticle matrix is adhered to in an external substrate-surface, such as the balloon surface, and is activated for release once at the treatment site. Activation for release may be enhanced through the use of an undulating balloon system including methodologies for precise control of timing, waveform and extent of undulations.

Method for manufacturing microcapsules enclosing a substance referred to as the active substance, in which method: there are provided an aqueous solution of a surfactant, an oily phase comprising the active substance and at least a first monomer X, and a polar phase having at least a second monomer Y; an O/W emulsion is prepared by adding the oily phase to the aqueous solution of the surfactant; the polar phase is added to the O/W emulsion in order to obtain a polymer by polymerisation of the X and Y monomers; starting from this reaction mixture, the microcapsules are isolated and comprise a wall which is formed by the polymer and which encloses the active substance; the polymer is a poly(beta-amino ester).

A cerium oxide nanocomplex, a composition containing the cerium oxide nanocomplex as an active ingredient, and their uses for preventing or treating inflammatory liver disease are disclosed. The present disclosure applies a biocompatible polymer composed of an optimal combination to significantly improve the biomedical stability, biosynthesis and efficiency of the production process of nanoparticles while maintaining the nanoparticles’ excellent inhibitory activity against inflammation. In particular, the present disclosure may be applied as an effective therapeutic composition that effectively controls excessive immune response and inflammatory response and tissue injury in acute liver failure which is a serious condition of rapid loss of liver function that results in multiple organ failure and death.

The present invention relates to a method for producing an andrographolide carrier system, comprising: (i) preparing a dispersed phase by dissolving andrographolide in ethanol solvent; (ii) preparing an inner encapsulating carrier layer; (iii) forming a protective encapsulating layer of the active agent; (iv) forming bonds to attach mucoadhesion enhancers onto the surface structure of the encapsulating layer, and then bringing the mixture to room temperature, slowly adding hydroxypropyl methylcellulose HPMC; (v) heating until the temperature reaches 50° C., adding Polysorbate 80 and PEG-40 hydrogenated castor oil to the mixture, with further stirring under vacuum; and (vi) filtering the product by injection through a nanofilter system.

A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W.sub.1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

Materials and methods for using genistein to treat respiratory distress syndrome or acute lung injury (e.g., pneumonitis, pulmonary fibrosis, dyspnea, pneumonia, and/or pulmonary edema resulting from viral infection, including SARS-CoV-2 infection) are provided herein.

Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.